Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium
Magali Cazade1, Cindy E Nuss, Isabelle Bidaud
1Institut de Génomique Fonctionnelle, Universités Montpellier 1 and 2, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5203, Institut National de la Santé et de la Recherche Médicale U661, LabEx Ion Channel Science and Therapeutics, Montpellier, France (M.C., I.B., P.L., J.C.); and Department of Neuroscience, Merck Research Laboratories, West Point, Pennsylvania (C.E.N., J.J.R., V.N.U.).
Abstract:
T-type calcium channels (T/Ca(v)3-channels) are implicated in various physiologic and pathophysiologic processes such as epilepsy, sleep disorders, hypertension, and cancer. T-channels are the target of endogenous signaling lipids including the endocannabinoid anandamide, the ω3-fatty acids, and the lipoamino-acids. However, the precise molecular mechanism by which these molecules inhibit T-current is unknown. In this study, we provided a detailed electrophysiologic and pharmacologic analysis indicating that the effects of the major N-acyl derivatives on the Ca(v)3.3 current share many similarities with those of TTA-A2 [(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide], a synthetic T-channel inhibitor. Using radioactive binding assays with the TTA-A2 derivative [(3)H]TTA-A1 [(R)-2-(4-(tert-butyl)phenyl)-N-(1-(5-methoxypyridin-2-yl)ethyl)acetamide], we demonstrated that polyunsaturated lipids, which inhibit the Ca(v)3.3 current, as NAGly (N-arachidonoyl glycine), NASer (N-arachidonoyl-l-serine), anandamide, NADA (N-arachidonoyl dopamine), NATau (N-arachidonoyl taurine), and NA-5HT (N-arachidonoyl serotonin), all displaced [(3)H]TTA-A1 binding to membranes prepared from cells expressing Ca(v)3.3, with Ki in a micromolar or submicromolar range. In contrast, lipids with a saturated alkyl chain, as N-arachidoyl glycine and N-arachidoyl ethanolamine, which did not inhibit the Ca(v)3.3 current, had no effect on [(3)H]TTA-A1 binding. Accordingly, bio-active lipids occluded TTA-A2 effect on Ca(v)3.3 current. In addition, TTA-Q4 [(S)-4-(6-chloro-4-cyclopropyl-3-(2,2-difluoroethyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl)benzonitrile], a positive allosteric modulator of [(3)H]TTA-A1 binding and TTA-A2 functional inhibition, acted in a synergistic manner to increase lipid-induced inhibition of the Ca(v)3.3 current. Overall, our results demonstrate a common molecular mechanism for the synthetic T-channel inhibitors and the endogenous lipids, and indicate that TTA-A2 and TTA-Q4 could be important pharmacologic tools to dissect the involvement of T-current in the physiologic effects of endogenous lipids.
Insights
Synthetic T-channel inhibitors and endogenous lipids share a common molecular mechanism for inhibiting T-type calcium channels (T/Ca(v)3-channels). This finding reveals potential new pharmacologic tools for studying T-current
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- T-type calcium channels (T/Ca(v)3-channels) are crucial in physiological and pathophysiological processes like epilepsy and hypertension.
- Endogenous signaling lipids, including anandamide and omega-3 fatty acids, are known to target T-channels, but their precise inhibitory mechanism remains unclear.
Purpose of the Study:
- To elucidate the molecular mechanism by which N-acyl derivatives and synthetic inhibitors affect T-type calcium currents.
- To investigate the interaction between synthetic inhibitors (TTA-A2, TTA-Q4) and endogenous lipids at the Ca(v)3.3 channel.
Main Methods:
- Detailed electrophysiologic and pharmacologic analysis of Ca(v)3.3 currents.
- Radioactive binding assays using [(3)H]TTA-A1 to assess lipid interactions with Ca(v)3.3 channels.
- Investigating the effects of lipids and modulators (TTA-A2, TTA-Q4) on T-channel activity.
Main Results:
- Polyunsaturated lipids (anandamide, NAGly, NASer, NADA, NATau, NA-5HT) displaced [(3)H]TTA-A1 binding to Ca(v)3.3 channels, indicating a shared binding site.
- Saturated lipids did not affect [(3)H]TTA-A1 binding or T-channel inhibition, unlike unsaturated lipids.
- Bioactive lipids occluded the inhibitory effect of TTA-A2 on Ca(v)3.3 current, and TTA-Q4 synergistically enhanced lipid-induced inhibition.
Conclusions:
- Synthetic T-channel inhibitors (TTA-A2) and endogenous lipids share a common molecular mechanism of action on Ca(v)3.3 channels.
- TTA-A2 and TTA-Q4 represent valuable pharmacological tools for dissecting the physiological roles of T-current in response to endogenous lipids.
More Related Videos
10:46Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells
Published on: July 16, 2013
09:45Simultaneous Measurements of Intracellular Calcium and Membrane Potential in Freshly Isolated and Intact Mouse Cerebral Endothelium
Published on: January 20, 2019
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antihypertensive Drugs: Action of Calcium Channel Blockers
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...
G-Protein Gated Ion Channels
Sensory...
IP3/DAG Signaling Pathway
